Navigation Links
MDS Nordion Divests Non Strategic Product Lines
Date:11/29/2007

Signs contract with Best Medical International Inc.

OTTAWA, Nov. 29 /PRNewswire-FirstCall/ - MDS Nordion, a leading provider of medical isotopes and radiopharmaceuticals, today signed an agreement with Best Medical International Inc. to divest its external beam therapy and self-contained irradiator product lines. The sale is a key part of MDS Nordion's growth strategy to focus its resources on being a leading innovator in molecular medicine.

Under the terms of this agreement, Best Medical International Inc., a provider of radiotherapy and oncology products, will purchase MDS Nordion's external beam therapy and self-contained irradiator product lines. External beam therapy equipment is used in the treatment of cancer, and self-contained irradiators are used for the irradiation of blood to prevent disease and for research purposes. Best Medical International Inc. will acquire these two product lines with combined annualized revenues of US $32 million and approximately 150 employees. The transaction is expected to close over the next three months. The financial terms are not being disclosed.

"This sale represents a further focusing of our business at MDS Nordion," said Steve West, President, MDS Nordion. "By divesting these product lines, we can direct all of our energy and resources on becoming a leading innovator in the exciting and growing field of molecular medicine."

The external beam therapy units and blood irradiators are complementary to the kinds of medical equipment manufactured by Best Medical International Inc. With a strategic focus on improving medical care in developing countries, Best Medical International Inc. will provide an opportunity to expand these product lines.

"These product lines are a great fit with our company," said Krishnan Suthanthiran, President, Best Medical International Inc. "The external beam cancer therapy product line complements our portfolio as we will now be able to offer the equ
'/>"/>

SOURCE MDS Nordion
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. MDS Nordion signs 17-year contract with Rosenergoatom
2. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
3. Martopia(R) Forms Strategic Alliance With Modern Healthcare Magazine
4. LehmanMillet Continues Expansion with Strategic Hires
5. Stille and Enova Form Strategic Partnership to Introduce Worlds Brightest LED Cordless Surgical Headlights Into Europe and Japan
6. Benjamin England, Former FDA Regulatory Counsel, to Testify on FDA Import Strategic Plan Before House Appropriations Subcommittee
7. Diet.com Enters Strategic Collaboration To Support Microsoft HealthVault
8. Lumenis Ltd. Announces Senior Leadership Appointments Strengthening the Companys Strategic Businesses
9. Avantium and BP Extend Strategic Partnership
10. 40 86 Strategic Income Fund Declares Dividend
11. Medco, LabCorp Strike Strategic Agreement for Research on Personalized Medicine and Pharmacogenomics
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:MedQuist and Clario Form Partnership to Integrate zVision Radiology Practice Management Software with SpeechQ for Radiology 2Health News:MedQuist and Clario Form Partnership to Integrate zVision Radiology Practice Management Software with SpeechQ for Radiology 3Health News:Turn the Corner Honors Andy Abrahams Wilson, Director of Under Our Skin, for His Dedication in the Fight Against Lyme Disease 2Health News:Turn the Corner Honors Andy Abrahams Wilson, Director of Under Our Skin, for His Dedication in the Fight Against Lyme Disease 3Health News:Corgenix Reports Financial Results for First Quarter of Fiscal 2009 2Health News:Corgenix Reports Financial Results for First Quarter of Fiscal 2009 3Health News:Natural Nutrition Canadian Subsidiary Signs $50.5 Million (CDN) Five Year European Distribution Contract 2Health News:KV Pharmaceutical Company Files Form Reporting Delay in Filing Second Quarter Form 10-Q 2Health News:KV Pharmaceutical Company Files Form Reporting Delay in Filing Second Quarter Form 10-Q 3Health News:KV Pharmaceutical Company Files Form Reporting Delay in Filing Second Quarter Form 10-Q 4Health News:Employers Want National Approach to Health Care—Still Believe Employer-Based System Works Best: New Survey Looks At Attitudes toward Health Care Reform and Major Health Care Issues. 2Health News:Employers Want National Approach to Health Care—Still Believe Employer-Based System Works Best: New Survey Looks At Attitudes toward Health Care Reform and Major Health Care Issues. 3
Breaking Medicine Technology:Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 2Echo Therapeutics Announces Consulting Agreement with Hayden IR to Develop and Implement a Strategic Investor Relations Campaign 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010 2China-Biotics, Inc. to Hold 2009 Annual Meeting of Stockholders on March 5, 2010 3Sex based prenatal brain differences found 10503 1Sex based prenatal brain differences found 10503 2Bladder Problems May Often Be Related to Mental Health 59989 1Bladder Problems May Often Be Related to Mental Health 59989 2Why antidepressants dont work for so many 59985 1Why antidepressants dont work for so many 59985 2Why antidepressants dont work for so many 59985 3